Table 5.
Unadjusted and adjusted analyses for the risk of NAFLD in postmenopausal women.
| Unadjusted OR (95% CI) | P | Adjusted OR (95% CI) | P | |
|---|---|---|---|---|
| Age | 1.03 (0.99–1.06) | 0.124 | 0.97 (0.93–1.01) | 0.179 |
| Hypertension | 2.68 (1.73–4.17) | <0.001 | 1.50 (0.86–2.61) | 0.152 |
| Diabetes | 3.57 (2.22–5.74) | <0.001 | 2.38 (1.30–4.37) | 0.005 |
| Triglyceridemia | 5.57 (3.09–10.03) | <0.001 | 4.51 (2.16–9.43) | <0.001 |
| HDL | 0.46 (0.29–0.75) | 0.002 | 0.85 (0.46–1.57) | 0.592 |
| Central obesity | 4.91 (3.10–7.76) | <0.001 | 4.17 (2.40–7.23) | <0.001 |
| Hormone therapy | 0.03 (0.13–0.88) | 0.026 | 0.47 (0.15–1.44) | 0.185 |
| Smoking | 0.78 (0.21–2.89) | 0.713 | 0.56 (0.13–2.45) | 0.439 |
| Exercise | 1.59 (0.96–2.62) | 0.072 | 1.35 (0.74–2.48) | 0.332 |
| ALT | 1.07 (1.04–1.10) | <0.001 | 1.07 (1.04–1.10) | <0.001 |
| GGT | 1.01 (1.00–1.02) | 0.022 | 0.99 (0.98–1.00) | 0.122 |
| HOMA | 1.72 (1.37–2.16) | <0.001 | 1.02 (0.84–1.24) | 0.838 |
NAFLD: nonalcoholic fatty liver disease; ALT: alanine aminotransferase; GGT: gamma-glutamyl transpeptidase; OR: odds ratio; CI: confidence interval; HDL: high density lipoprotein; HOMA: homeostasis model assessment-estimated insulin resistance.